PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32005799-5	2020	Interruption of IL-6/JAK/STAT3 pathway by a JAK inhibitor AZD1480 reverses the pro-metastatic effect of sevoflurane and the associated increase of both activated STAT3 and infiltrated CD11b+ cells in 4T1 model.	AZD 1480	58-65	interleukin 6	Homo sapiens	16-20	
32768575-10	2020	Inhibition of the IL-6/JAK/STAT3 pathway with the JAK1/2 specific inhibitor, AZD1480, reversed the associated increase of IL-6.	AZD 1480	77-84	interleukin 6	Homo sapiens	18-22	
32768575-10	2020	Inhibition of the IL-6/JAK/STAT3 pathway with the JAK1/2 specific inhibitor, AZD1480, reversed the associated increase of IL-6.	AZD 1480	77-84	interleukin 6	Homo sapiens	122-126	
21164517-2	2011	We investigated the effects of a novel small-molecule JAK inhibitor (AZD1480) on IL-6/JAK signal transduction and its biological consequences on the human myeloma-derived cell lines U266 and Kms.11.	AZD 1480	69-76	interleukin 6	Homo sapiens	81-85	
29722127-8	2018	Application of the JAK2 inhibitor AZD1480 and IL6 neutralizing antibody showed the CD90 and SHH/Gli-regulated liver cancer stem cell functions were mediated by the IL6/JAK2/STAT3 pathway.	AZD 1480	34-41	interleukin 6	Homo sapiens	164-167	
25216185-2	2014	To develop novel therapies for CRC, we have explored the effects of a novel small-molecule JAK inhibitor (AZD1480) on IL-6/JAK/STAT3 pathway and its potential antitumor activity on the human CRC cell lines (HCT116, HT29 and SW480).	AZD 1480	106-113	interleukin 6	Homo sapiens	118-122	
25216185-3	2014	The results showed that, AZD1480 effectively prevents constitutive and IL-6-induced JAK2 and STAT-3 phosphorylation and exerted antitumor functional effects by a decrease in proliferation and an increase in apoptosis in CRC cells.	AZD 1480	25-32	interleukin 6	Homo sapiens	71-75